Biocryst Pharmaceuticals, Inc. (BCRX) rated Mkt Outperform with price target $7 by Rodman & Renshaw
Rodman & Renshaw rated Mkt Outperform Biocryst Pharmaceuticals, Inc. (NASDAQ: BCRX) on 09/29/2010, when the stock price was $5.01.
Since then, Biocryst Pharmaceuticals, Inc. has gained 102.59% as of 02/25/2015's recent price of $10.15. If you would have followed this Rodman & Renshaw's recommendation on BCRX, you would have gained 102.59% of your investment in 1610 days.
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
Rodman & Renshaw
is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.